Lisa K. Jennings, PhD
Lisa K Jennings, PhD founded CirQuest Labs in 2008 as an extension of her successful basic and translational research program
as a faculty member at the University of Tennessee Health Science Center. An internationally recognized leader in anti-platelet and anticoagulant therapies, she has served on numerous industry scientific and clinical development advisory boards. She has been instrumental in assisting industry in the design and implementation of mechanistic studies and clinical trials in the vascular biology field, including CAD, stroke, PAD, inflammatory and metabolic diseases, hematology, and medical device fields.
Dr. Jennings was also Director of the UTHSC Vascular Biology Center of Excellence and Professor of Medicine at the University of Tennessee Health Science Center (UTHSC) in Memphis, Tennessee. She had secondary appointments as Professor in the Departments of Molecular Sciences and Surgery as well as in the Joint Program of Biomedical Engineering at UTHSC and the University of Memphis. She was also the Director of the Tennessee-Arkansas-Mississippi (TAM) Clinical Research Consortium. Currently, she is a Clinical Professor in the Department of Internal Medicine at UTHSC.
Dr. Jennings attended graduate school at UTHSC completing her doctoral research projects at St. Jude Children’s Research Hospital and the Gladstone Foundation Laboratories in San Francisco, CA. During her training she was instrumental in the isolation and characterization of the platelet GPIIb-IIIa receptor, the key integrin on platelets that mediates platelet thrombus formation. She completed a postdoctoral fellowship at St. Jude Children’s Research Hospital, where she was a Leon Journey Fellow, and was appointed to the faculty of UTHSC in 1985.
Dr. Jennings has an established research program in the area of platelet and vascular smooth muscle cell biology, specifically the function of surface membrane receptors and associated signaling pathways. She has internationally- recognized expertise in the development, study and evaluation of antiplatelet agents and anticoagulants, including the design and conduct of the pharmacodynamic assessment of these agents in preclinical/translational studies and clinical trials. Clinical trials with which she has been involved include IMPACT, IMPACT II, PRIDE, ESPRIT, and PROTECT trials of eptifibatide, PYRAMID (YM337), ORATOR, TIMI 15A and B, PICOLO (clopidogrel), TRA-PCI, ATLAS, ROCKET-AF, TRACER, APEX, and UTHSC investigator-initiated studies via the TAM Consortium.
Her other research efforts concentrate on vascular injury response and inflammation, particularly signaling pathways associated with neointimal hyperplasia and atherogenesis. In addition, she is a founding member of ARISTE Medical, LLC dedicated to reducing complications of implantable devices. Dr. Jennings is taking these years of experience and expertise in the field into product development services.